EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Les biothérapies en 2023 dans l’asthme sévère de l’enfant

F Amat

Revue des Maladies Respiratoires · 2023

DOI: 10.1016/j.rmr.2023.09.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Revue des Maladies Respiratoires, 2023. Verfasst von F Amat. Beteiligte Einrichtung: Service de pneumologie et d'allergologie pédiatrique, CRCM, hôpital Robert-Debré, AP-HP, 48, boulevard Sérurier, 75019 Paris, France; Inserm 1018, Ce…. Hauptthemen laut MEDLINE: Asthma, Biological Products, Anti-Asthmatic Agents. Die Arbeit nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Severe asthma in children remains relatively rare. It is no longer considered as a single disease but rather as a syndrome corresponding to different phenotypes and distinct pathophysiological pathways. Various biomarkers can contribute to phenotyping, essentially specific IgE test results, blood eosinophil counts, the exhaled fraction of NO (FeNO) assay, as well as deep lung biomarkers from induced sputum, bronchoalveolar lavage or bronchial biopsy. STATE OF KNOWLEDGE: In children, the biologics currently approved for severe asthma are omalizumab, mepolizumab and dupilumab from the age of 6, and tezepelumab from the age of 12. PERSPECTIVES: Benralizumab and tezepelumab offer promising perspectives and a pediatric extension could be of interest in future treatment of severe pediatric asthma. CONCLUSIONS: Based on physiopathological mechanisms, biologics represent a new and promising approach in the treatment of asthma. That said, the long-term efficacy and impact of these treatments on the natural history of the disease require further investigation. It is of paramount importance to take into account the specificities of pediatric asthma and, more particularly, to conduct clinical trials in younger patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaBiological ProductsAnti-Asthmatic AgentsHumansChildAntibodies, Monoclonal, HumanizedSeverity of Illness IndexOmalizumab

Stichwörter der Autor:innen

BenralizumabDupilumabMepolizumabMépolizumabOmalizumabTezepelumab

Substanzen

Biological ProductsAnti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedmepolizumabOmalizumabbenralizumab

Autor:innen und Institutionen

  • Service de pneumologie et d'allergologie pédiatrique, CRCM, hôpital Robert-Debré, AP-HP, 48, boulevard Sérurier, 75019 Paris, France; Inserm 1018, Centre de recherche en épidémiologie et santé des populations, épidémiol…

Zitieren

APA

Amat, F. (2023). Les biothérapies en 2023 dans l’asthme sévère de l’enfant. Revue des Maladies Respiratoires. https://doi.org/10.1016/j.rmr.2023.09.002

Vancouver

Amat F. Les biothérapies en 2023 dans l’asthme sévère de l’enfant. Revue des Maladies Respiratoires. 2023. doi:10.1016/j.rmr.2023.09.002

BibTeX
@article{Amat2023,
  author = {Amat, F},
  title = {Les biothérapies en 2023 dans l’asthme sévère de l’enfant},
  journal = {Revue des Maladies Respiratoires},
  year = {2023},
  doi = {10.1016/j.rmr.2023.09.002}
}
Kostenlos starten →